| 棕榈酸帕利哌酮PP1M治疗精神分裂症的药物经济学研究进展 |
| |
| 引用本文： | 郑慧,金金,蔡军,谢斌. 棕榈酸帕利哌酮PP1M治疗精神分裂症的药物经济学研究进展[J]. 实用药物与临床, 2021, 24(3): 270-275 |
| |
| 作者姓名： | 郑慧 金金 蔡军 谢斌 |
| |
| 作者单位： | 上海交通大学医学院附属精神卫生中心,上海200030;上海交通大学医学院附属精神卫生中心,上海200030;上海交通大学医学院附属精神卫生中心,上海200030;上海交通大学医学院附属精神卫生中心,上海200030 |
| |
| 基金项目： | 上海市卫生计生系统重要薄弱学科建设计划(2015-ZB0405);上海市“科技创新行动计划”临床医学领域项目(19411950801);上海市公共卫生体系建设三年行动计划(2020-2022年)重点学科建设计划项目(GWV-10.1-XK18)。 |
| |
| 摘 要： | 目的 系统总结棕榈酸帕利哌酮(PP1M)治疗精神分裂症的药物经济学相关研究结果,为抗精神病药的临床应用提供依据.方法 系统检索Taylor&Francis、ScienceDirect、PubMed、Embase、CBM、中国知网和万方数据库等,检索时间从建库至2019年12月,纳入2015～2019年棕榈酸帕利哌酮(P...
|
| 关 键 词： | 棕榈酸帕利哌酮 精神分裂症 抗精神病药 药物经济学 |
Research process in pharmacoeconomic evaluation of paliperidone palmitate(PP1M)in the treatment of schizophrenia |
| |
| ZHENG Hui,JIN Jin,CAI Jun,XIE Bin. Research process in pharmacoeconomic evaluation of paliperidone palmitate(PP1M)in the treatment of schizophrenia[J]. Practical Pharmacy and Clinical Remedies, 2021, 24(3): 270-275 |
| |
| Authors: | ZHENG Hui JIN Jin CAI Jun XIE Bin |
| |
| Affiliation: | (Shanghai Mental Health Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China) |
| |
| Abstract: | Objective To systematically review the results of pharmacoeconomics-related studies on the treatment of schizophrenia with paliperidone palmitate(PP1 M),so as to provide evidence for the clinical application of antipsychotics.Methods Taylor&Francis,ScienceDirect,PubMed,Embase,CBM,CNKI and Wanfang databases were systematically searched from their establishment to December 2019,and the literatures related to pharmacoeconomics of paliperidone palmitate(PP1 M)from 2015 to 2019 were included.The quality of literatures was evaluated with reference to Consolidated Health Economic Evaluation Reporting Standards(CHEERS)scale.Results A total of 14 controlled studies were included to evaluate the efficacy,cost savings,and Quality Adjusted Life Years(QALYs)of paliperidone palmitate(PP1 M)as compared to other antipsychotics.Most of the results supported the superior efficacy of paliperidone palmitate(PP1 M),and the stability of the results was verified by sensitivity analysis.Conclusion Among the current antipsychotic drugs,paliperidone palmitate(PP1 M)has a good pharmacoeconomic advantage in the treatment of schizophrenia.Meanwhile,the cost-effective advantage of paliperidone palmitate(PP3 M)is more obvious. |
| |
| Keywords: | Paliperidone palmitate Schizophrenia Antipsychotics Pharmacoeconomics |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
